Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

Key Eligibility:
• Pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer within 60 days prior to registration.
• Patients must have received one cycle of platinum/etoposide chemotherapy prior to study registration, with study registration required within 21 days from day 1 of first cycle of chemotherapy and protocol treatment designed to begin 21 days after initiation of cycle 1. If patient has not recovered from cycle 1 chemotherapy toxicities, then an additional 14 days is permitted.
• Patients must have had measurable disease prior to the required cycle of platinum/etoposide chemotherapy.
• History/physical examination within 30 days prior to registration.
Phase II/III
Dan Zuckerman, M.D.
NRG (NRG Oncology)
Brenda Fisher

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.